Loading
Cancer usually kills by spreading to bone, liver, lung or brain. Almost all laboratory models grow tumours under the skin instead, where the surroundings are nothing like those organs.
Subcutaneous xenografts remain the default despite being the least relevant site. Engineered bone marrow niches, liver-on-chip with resident macrophages, and perfused lung and brain models can be seeded with patient tumour cells to study colonisation, dormancy and organ-specific drug response. Organ-specific microenvironments determine both seeding and treatment sensitivity.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived xenografts, Lab models that fail to predict what happens in patients.